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SUMMARY  
Many investigators have reported cyclic proliferation of normal human breast epithelial cells. A delicate balance 
between proliferation and apoptosis (programmed cell death) ensures breast homeostasis. Both the follicular and 
luteal phases of the menstrual cycle are characterized by proliferation, whereas apoptosis occurs only at the end 
of the latter phase. In this study, we observed that the withdrawal of a synthetic progestin (nomegestrol acetate or 
NOMAC), but not continuous treatment with it, induced apoptosis of normal human breast epithelial cells in 
vitro and in women who applied NOMAC gel to their breasts. Furthermore, this apoptotic response was specific 
to normal breast cells, since withdrawal of NOMAC did not induce apoptosis of tumoral T47D cells in vitro or 
of fibroadenoma cells in women. These observations open up new perspectives in the prevention of hyperplasia 
and breast cancer.  
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INTRODUCTION 
It is essential that cell number be controlled during processes involving the renewal of tissues in both embryos 
and adults. This control relies on a delicate balance between proliferation and cell death. Proliferation and 
apoptosis (programmed cell death) have indeed been implicated in several normal processes, such as tissue 
development and homeostasis, but also in certain pathologic states.1,2
In the 'resting' human breast, epithelial cell proliferation has been reported to peak during the follicular3,4 and 
luteal phases of the menstrual cycle.5-8 On the other hand, Ferguson and Anderson, in 1981, noted the highest 
percentage of apoptotic cells during menstruation.5 The expression of Bcl-2, which inhibits apoptosis,9 is 
maximal in breast epithelial cells during ovulation and then declines dramatically as the number of cells affected 
by apoptosis rises.10 This sequence of events suggests that Bcl-2 expression and apoptosis are directly or 
indirectly influenced by ovarian steroid hormones.11-13 The premenstrual period is characterized by a rapid 
decrease of serum levels of progesterone. Therefore, in the present study, we examined the effects of a progestin 
(17α-acetoxy-6-methyl-nor-pregna-4,6-diene-3,20-dione: nomegestrol acetate, NOMAC, LUTENYL™) on the 
apoptosis of normal breast epithelial cells, both in vitro and in vivo. NOMAC, a 19-norprogesterone derivative, 
lacks estrogenic activity, as demonstrated by estrogen receptor-binding assays, growth assays using MCF-7 and 
T47D:A18 cells, and transient transfection studies.14 Its half-life, which is longer than 3 days in the culture 
medium of T47-D cells,15 affords highly steady-state concentrations if the medium is renewed daily. 
In addition, to determine whether the apoptotic process could be modified in the context of a pathologic 
condition, we also evaluated the responses to this progestin of T47D breast epithelial tumor cells in vitro and of 
epithelial cells of fibroadenomas in vivo. 
MATERIALS AND METHODS 
In vitro studies 
Cell cultures 
Human mammary epithelial cells (HMECs) were isolated from tissues obtained from reduction mammoplasties 
and processed immediately after surgery as previously described.16 Primary cultures were grown in DMEM/F12 
(GIBCO), 5% fetal calf serum (FCS), 0.5 µg/ml of hydrocortisone (Sigma), 10 µg/ml of insulin (Sigma), 0.05 
µg/ml of cholera toxin (Sigma), 5 µg/ml of EGF (Sigma), and 100 IU/100 µg/ml of penicillin/ streptomycin 
(Sigma). The culture medium was changed every 3 days, and the primary cells used in the experiment were 
harvested after one trypsinization of 15-day-old cultures. The epithelial nature of the cells was confirmed in 
antikeratin 8-18 antibody (Beckton-Dickinson) labeling studies. The human mammary tumor cell line T47D was 
obtained from American Type Cell Culture and cultured in RPMI 1640 medium (Gibson), 10% FCS, 100 IU/100 
µg/ml of penicillin/ streptomycin according to ATCC recommendations. 
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Hormonal treatments 
The primary cultures of HMEC (15000 cells/well) and T47D cells (10000 cells/well) were seeded on plastic 
coverslips (Thermanox). After 48 h, the medium was replaced with fresh steroid-free medium (without red 
phenol) supplemented with dextran-charcoal-treated serum until half-confluency was reached (50% saturation). 
Cells were then cultured in three different conditions: (A) in a steroid-free medium containing 0.1% ethanol for 6 
days; (B) in the presence of steroid-free medium containing 10-7 M NOMAC dissolved in 0.1% ethanol, with the 
medium changed once a day; (C) in the presence of steroid-free medium containing 10-7 M NOMAC dissolved in 
0.1% ethanol for 3 days, and subsequently in the same medium but with no NOMAC. The medium was replaced 
every 24 h and the cultures were arrested 6, 12, 18, 24, 30, 36 or 42 h after NOMAC withdrawal. 
In situ detection of apoptosis 
Terminal dUTP nick-end labeling (TUNEL)17 was used to detect free 3'-end OH groups in situ in fragmented 
DNA according to the manufacturer's instructions (In Situ Cell Death Detection Kit, Boehringer Mannheim), 
albeit with some modifications: cultures were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) 
at room temperature for 15 min and permeabilized with ice-cold methanol at -20°C for 10 min. Cells were rinsed 
with 70% ethanol, rehydrated twice with PBS for 10 min, and incubated with the TUNEL reaction mixture 
(containing terminal deoxynucleotidyl transferase and fluorescein-labeled low-molecular-weight DNA 
fragments) for 1 h. Apoptotic cells were revealed by alkaline phosphatase-coupled anti-fluorescein antibody 
(provided in the kit), and New Fuchsine Substrate System (Dako). Cells were counterstained with hematoxylin 
and eosin. Apoptotic (red nucleus) and viable (blue nucleus) cells were counted for each culture condition. 
Automated quantitative immunolabeling analysis was performed using a computer-assisted image processor 
(CAS 200), as previously described.18 At least 1000 nuclei were counted for each well. Appropriate positive 
controls (HMEC incubated with Dnase I to induce strand breaks) and negative controls (HMEC incubated with 
fluorescein-labeled DNA fragments without terminal transferase) were included. 
Caspase-3 activity 
Caspase-3 (Yama/apopain/CPP32) is an enzyme similar to interleukin 1β-converting enzyme that is implicated 
in apoptosis.19,20 Its activity was measured as previously described.20 HMEC or T47-D were plated onto 85-mm-
diameter dishes and grown to 75% confluence (2.5 x 106 cells). After hormone treatment, they were rinsed in 
PBS, detached by scraping, and placed on ice for 2 h in lysis buffer containing protease inhibitors [50 mM Tris, 
pH 7.4, 1 mM ethylenediamine tetraacetic acid (EDTA), 10 mM ethylene glycol tetraacetic acid (EGTA), and 
0.2 mM phenylmethylsulfonyl fluoride (PMSF)]. Cell lysates were then centrifuged at 1500 g for 10 min, and 
supernatants were collected and kept on ice. The protein concentration was adjusted to 90 µg/ml in AFC-120 
buffer [50 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid) pH 7.5, 1% sucrose, 0.1% 
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)]. Dithiothreitol was added to give a 
final concentration of 10 mM. Caspase-3 fluorogenic substrate Ac-DEVD-AFC (N-acetyl-Asp-Glu-Val-Asp-
AFC, Enzyme Systems Products) was diluted in 2.5 mM DMSO and added to samples (final concentration 50 
µM). Fluorescence changes were monitored with a Perkin-Elmer MPF-44B fluorescence spectrophotometer 
(excitation wavelength: 400 nm; emission wavelength: 505 nm) at various times over 32 h. Lysates of freshly 
isolated or overnight-cultured murine lymphocytes were used as negative and positive controls, respectively.21 
Each measure was done in triplicate. 
Caspase-3 inhibition 
The caspase-3 inhibitor Ac-DEVD-CHO (N-acetyl-Asp-Glu-Val-Asp-CHO(aldehyde), Enzyme Systems 
Products) was added to the medium (50 µl/ml of medium) at the same time as NOMAC was withdrawn. Cells 
were fixed and analyzed using the TUNEL technique described above. Each measurement was done in triplicate. 
SDS-PAGE and immunoblotting 
After two or four trypsinizations, HMEC were cultured and treated with NOMAC for 3 days in steroid-free 
medium as described above. Those cells were then lysed (50 µg protein) and subjected to SDS-PAGE and 
immunoblotting as described previously.22 Separated proteins were transferred onto microporous polyvinylidene 
fluoride membranes (NEN, USA) and blocked with Tris-buffered saline containing 3% of bovine serum albumin 
(BSA). Membranes were probed with rabbit anti-human progesterone-receptor type B (PR-B) (DAKO, 
Denmark). Following primary antibody incubation, membranes were washed and then incubated with peroxidase 
conjugated swine anti-rabbit immunoglobulins (DAKO). Immunoreactive protein bands were visualized by 
enhanced chemiluminescence on Kodak medical film. T47D cells were included for positive controls, and skin 
fibroblasts (kindly provided by Dr Charlie Lambert, Laboratory of Biology of Connective Tissues, CHU of 
Liège), for negative controls. 
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In vivo studies 
Patients 
The study was designed as a prospective, randomized, double-blind trial. Forty premenopausal women (mean 
age 32.8 ± 11.6 years, range 16-53 years) with documented spontaneous regular menstrual cycles were enrolled 
in this study. Previous hormonal contraception was discontinued. Twenty of these women had requested a 
reduction mammoplasty and had no known breast pathology (normal breast group). The others underwent 
removal of a fibroadenoma, which had been diagnosed clinically and radiologically and confirmed histologically 
(fibroadenoma group). In each group, the women were randomly and blindly assigned to one of two treatment 
groups and received a hydro-alcoholic gel (2 g/day) containing either NOMAC 2.2 g/day or a placebo. Each gel 
formulation was applied daily to both breasts for 14 days prior to surgery, from the first to the 14th (±1) day of 
the menstrual cycle. Surgery was performed on the 15th day of the menstrual cycle. The study design was 
approved by the University of Liège Ethics Committee, and oral informed consent was obtained from each 
woman. 
Study design 
Surgery was performed on the 15th day of the menstrual cycle, before exposure to endogeneous progesterone 
produced by the corpus luteum during the postovula± tory phase of the cycle. The gel was applied for the last 
time 24-30 h before surgery. During surgery, a blood sample was taken for plasma level measurements of 
estradiol (E2), progesterone (P) (DPC Diagnostic Products), and sex hormone-binding globulin (SHBG) 
(Biocode). The absence of ovulation was verified by measurement of the plasma levels of progesterone which 
remained below 6-20 ng/ml. The presence of comparable values for SHBG in each of the four test groups is 
indicative of tissue exposure to comparable levels of endogenous estrogens, which are known to regulate 
progesterone receptor expression. The plasma levels of estradiol did not differ significantly in the four groups 
tested but showed considerable interindividual variation (Table 1). The women were thus exposed predominantly 
to the synthetic progestin or to placebo. Plasma NOMAC levels were measured by SPI/BIO (Gif-sur-Yvette, 
France). Two samples of normal breast tissue or fibroadenoma were set aside for this study. The first was stored 
at -20°C and processed for measurement of the tissue concentrations of E2 and NOMAC using a specific RIA 
already described elsewhere.18 The second sample was fixed and used for semi-quantitative evaluation of 
estradiol receptors (ERs) and progesterone receptors (PRs) using ER-RIA and PR-RIA kits (Abbott Diagnostics 
Division) and for detection of apoptosis by TUNEL, as described above except for the following modifications. 
Tissue sections were deparaffinized, rehydrated, and incubated with proteinase K 10 µg/ml in Tris/HCl for 10 
min at room temperature, and then with the TUNEL mixture for 1 h at 37°C. Slides were then incubated with 
peroxidase-coupled anti-fluorescein antibody (provided in the kit). Labeling was revealed by diaminebenzimide 
and slides were counterstained with methyl green (Sigma). Appropriate positive and negative controls were 
included. Semi-automated quantitative immunolabeling analysis was performed on a computer-assisted image 
processor (CAS 200) as described above. At least 2000 nuclei from the luminal epithelial and myoepithelial 
layers of the ducts and alveoli were evaluated for each tissue sample. All analyses were performed blind before 
the trial code was opened. All the patients whose histological examinations did not confirm their normal breast 
or fibroadenoma status were excluded from the study. 
 
Table 1    Plasma and tissue hormone levels as a function of breast pathology 
 Normal breasts Fibroadenoma 
 Placebo (n= 6) NOMAC (n = 6) Placebo (n = 7) NOMAC (n = 6) 
Plasma 
Estradiol (pg/ml) 30.9 ± 33.8 38.9 ± 51.4 70.4 ± 80 52 ± 32 
Progesterone (ng/ml) 2.7 ± 4.5 1.1 ± 1.3 2.6 ± 3.6 3.2 ± 6 
SHBG (pM/ml) 76.2 ± 79.4 73.8 ± 32.9 103 ± 77.7 62.8 ± 22.7 
NOMAC (ng/ml) BDL 0.39 ± 0.38 BDL 0.38 ± 0.27 
Tissue 
Estradiol (ng/g) 0.12 ± 0.04 0.14 ± 0.04 0.19 ± 0.07 0.19 ± 0.12 
NOMAC (ng/g) BDL 1.06 ± 0.57 BDL 0.38 ± 0.25 
BDL — below detection level. 
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RESULTS 
In vitro studies 
The primary cultures of HMEC remained viable and expressed PR as documented by SDS-PAGE and 
immunoblotting (Fig. 1). 
 
Apoptosis was evaluated using the TUNEL technique, in HMEC cultured continuously with a synthetic 
progestin, nomegestrol acetate (NOMAC), and at various time points after it had been withdrawn from the 
culture medium. Untreated control cells showed a low and constant level of apoptosis (8 ± 5% cells; n = 4). 
Similarly low levels of apoptosis (9 ± 6% cells; n = 4) were observed when cells were exposed to 10-7 M 
NOMAC continuously for 72 h. In contrast, the rate of apoptotic cells ranged between 3 ± 1% and 7 ± 5% cells 6 
and 12-18 h respectively after progestin withdrawal, but subsequently increased dramatically reaching 41 ± 14% 
(n = 4) after 24 h of hormonal deprivation. The proportion of cells undergoing apoptosis subsequently returned 
to low levels comparable to those in control cultures (9 ± 6%; n = 4, untreated cells or cells subjected to 
continuous treatment) (Fig. 2). 
For further characterization of the biochemical characteristics of the apoptotic response, caspase-3 activity was 
analyzed in cell lysates by using a specific fluorigenic substrate. The cascade of caspases is an autocatalytic 
cascade of proteases, which are responsible for the final steps of apoptosis. Caspase 9, the first step, activates 
caspase-3 (CPP32), which acts as a protease on some components of the cytoskeleton and a DNA-repairing 
enzyme (PARPP). Caspase-3 activity was consistently higher in cultures from which NOMAC had been 
withdrawn 24 h before than in untreated control cultures or cultures exposed to NOMAC continuously (Fig. 3). 
We therefore tested the effect of a caspase-3 inhibitor on the apoptosis of cells from which NOMAC had been 
withdrawn. When the caspase-3 inhibitor DEVD-CHO was added to the culture medium at the time of progestin 
withdrawal, apoptosis remained at control levels, as assessed by TUNEL (Fig. 2). As expected, this caspase-3 
inhibitor did not affect cell apoptosis either under control or under continuous NOMAC conditions (data not 
shown). 
 
Fig. 1    Expression of PR detected by SDS-PAGE and immunoblotting in HMECs cultured in the conditions 
used to show the apoptosis peak, after two (lane 3) or four passages (lane 4). T47D cells were used as a positive 
control (lane 1) and skin fibroblasts, as a negative control (lane 2). Expression of PR in HMEC was maintained 
in significant amounts after multiple trypsinizations and 3 days of NOMAC treatment (10-7 M). 
 
 
Absence of NOMAC-induced apoptosis in tumoral breast T47D cells 
To determine whether or not this apoptotic response to NOMAC withdrawal was specific to normal epithelial 
cells, human breast adenocarcinoma T47D cells expressing PR (demonstrated by SDS-PAGE immunoblotting as 
mentioned above) were subjected to NOMAC treatment and its withdrawal, and apoptosis was evaluated using 
the TUNEL technique and measurement of caspase-3 activity. Unlike the HMEC affected by apoptosis, T47D 
stained by the TUNEL technique and therefore apoptotic still accounted for under 1 ± 0.5% of all T47D cells         
(n = 4) 24 h after NOMAC withdrawal (Fig. 4), and caspase-3 activity also did not rise in the same conditions 
(Fig. 3). These findings suggest that the influence of progestin withdrawal on apoptosis observed in vitro is 
specific to normal mammary epithelial cells. 
In vivo studies 
Women with no known pathology (normal breast group) who had requested reduction mammoplasty and women 
undergoing fibroadenoma removal (fibroadenoma group) were enrolled in the present in vivo study. Only 25 (12 
in the normal breast group and 13 in the fibroadenoma group) of the 40 women initially enrolled completed the 
study. Most of the other 15 were excluded because of protocol irregularities. In the normal breast group, six 
patients received the NOMAC gel and six received the placebo gel. In the fibroadenoma group, six applied the 
NOMAC gel and 7 the placebo gel. The plasma levels of E2, P, SHBG, and NOMAC are shown in Table 1 and 
did not vary significantly among the groups. 
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In situ apoptosis detection 
Apoptosis was detected in breast sections using the TUNEL technique. The stromal cells of normal breast tissue 
or fibroadenoma did not differ significantly in their apoptosis levels, regardless of the treatment. The epithelial 
cells of NOMAC-treated normal breast exhibited significantly (P<0.01) higher levels of apoptosis than the 
corresponding placebo-treated cells (Table 2). In fibroadenomas, the rate of epithelial cell apoptosis was higher 
than in normal breast but did not vary according to breast exposure to progestin (Table 2). 
 
 
Fig. 2   HMEC apoptosis after NOMAC withdrawal and effect of caspase-3 inhibitor DEVD-CHO. Cells 
cultured as described in the 'Materials and methods' section were untreated (•), were continuously treated with 
NOMAC (■), or had NOMAC withdrawn at 0 h (▲). Caspase-3 inhibitor was able to block the apoptotic 
response observed after NOMAC withdrawal (♦). Apoptosis was detected by means of the TUNEL technique. 
Individual values shown are mean + standard deviation in four cultures in a representative experiment. Each 




Table 2   Number of TUNEL-positive cells per thousand cells as a function of breast pathology (expressed in 
medians and range) 
 Normal breast Fibroadenoma 
 Placebo NOMAC Placebo NOMAC 
Epithelial cells 19.97 (10.8-36) 53.7 (30.8-63)* 69.1 (53.8-79.1) 60.7 (41.6-89.4) 
Stromal cells 65.4 (53.5-71.5) 50.5 (35.2-61) 56.4 (32.9-84.6) 66.4 (13.1-79.6) 
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Fig. 3    Effect of NOMAC withdrawal or continuous treatment on apoptosis in HMEC and T47D tumor cells, 
assessed by measurement of caspase-3 activity. Cells cultured as described in the 'Materials and methods' 
section remained untreated, were treated with NOMAC administered daily or were initially treated with 
NOMAC, which was withdrawn after 24 h. This method of evaluation confirmed the peak of apoptosis induced 
24 h after withdrawal of NOMAC in HMEC, but not in T47D cells. 
 
 
Fig. 4 Effect of NOMAC on apoptosis of T47D cells detected by the TUNEL method. The rates of apoptosis 
remained low and relatively constant in cultures, whether the cells were untreated, continuously treated with 
NOMAC or subjected to NOMAC withdrawal, showing a lack of effect of NOMAC on T47D apoptosis in our 





Withdrawal of NOMAC from culture medium of normal HMECs in vitro triggered a marked apoptotic peak 24 h 
later, as demonstrated by in situ detection of fragmented DNA (TUNEL) and by measurement of the caspase-3 
activity, one of the main enzymes involved in apoptosis. Furthermore, addition of the caspase-3 inhibitor, 
DEVD-CHO, prevented apoptosis, thereby suggesting a key role for this enzyme in this endocrine regulation of 
apoptosis. Ferguson and Anderson5 previously observed a peak of apoptosis in the normal breast epithelium on 
day 28 of the menstrual cycle. This phenomenon could play an important part in the maintenance of tissue 
homeostasis, since it would be implicated in the balance between cell growth and cell death, allowing the cell 
number to remain constant from one cycle to another. 
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Our in vivo study shows that normal breast epithelial cells underwent apoptosis when a hydro-alcoholic gel 
containing NOMAC was applied once a day for 14 days. According to the protocol, progestin was applied for 
the last time 24-30 h before surgery. Therefore, it is tempting to speculate that it is the decreased tissular level of 
NOMAC that is responsible for the induction of apoptosis in the normal breast. In contrast, epithelial cells of 
fibroadenoma did not respond to this stimulus. The loss of such hormonal regulation of apoptosis could be 
implicated in the development of fibroadenomas, hyperplasias, and cancers.23,24 The data reported by Allan et 
al.25 support this hypothesis, as they showed a reduction of apoptosis relative to mitosis in histologically normal 
mammary epithelium located near fibrocystic lesions and carcinomas. It is indeed possible that benign epithelial 
cells of fibroadenoma could escape this hormonal regulation of apoptosis as a result of chronic exposure to 
various chemokines or cytokines present in the fibroadenomas. Other factors, such as the extracellular matrix 
and normal stromal cells of the breast, could also be involved in modulating the endocrine induction of 
mammary epithelial cells apoptosis.26-30
The peak of apoptosis induced by NOMAC withdrawal after 3 days of culture did not occur in human mammary 
T47D tumor cells, despite their constitutive expression of PR. The PR content of T47D, measured by the affinity 
method, has been shown to be strongly down-regulated by NOMAC after 6 days of continuous treatment.15 
However, Western blotting (Fig. 1) showed persisting expression of PR protein after 3 days of continuous 
NOMAC treatment, and in higher amounts than in HMEC cultured in the same conditions. Therefore, the 
absence of an apoptosis peak in T47-D cells after progestin deprivation cannot be ascribed to a lack of PR. On 
the contrary, it was continuous treatment with progestins and progesterone that induced apoptosis in T47-D cells, 
as shown by flow cytometry, morphological analysis, bcl-2 Western blotting,31 DNA laddering, and annexin 
V/propidium iodide staining.32 These apparently paradoxical results indicate that the hormonal regulation of 
apoptosis is altered in malignant cells, a process that could permit and/or promote tumor proliferation. 
Entry of the breast cell into G1 phase is necessary to trigger apoptosis, suggesting that proliferation and 
apoptosis are two different but related biochemical events. Several genes associated with G1 phase, including 
cyclin D1, D2 and D3 and c-fos, c-jun, junB, junD, c-myc, and p53, are induced both in proliferating and in 
apoptotic mouse mammary tissue. In the clone T47-D-YB, which constitutively expressed the B isoform of PR, a 
single dose of progesterone accelerates the cells' flux through the first mitotic cell cycle, but arrests or delays 
them late in G1 phase of the second cycle. Continuous treatment with multiple doses of progesterone chronically 
inhibits cell growth. In these conditions, progesterone is thus capable of stimulating or inhibiting cell growth, 
depending on whether treatment is transient or continuous, transient treatment being stimulatory and continuous 
treatment, inhibitory.33-38 The same biphasic effect of progestins on proliferation of normal mammary epithelial 
cells has been evoked as an explanation for the higher risk of breast cancer in hormone replacement therapy for 
menopausal complaints when sequential estrogens plus progestin compounds are used than when continuous 
combined therapy is given.39,40 Gompel et al.41 observed a proapoptotic effect of continuous exposure of HMEC 
to Org2058 (another 19-norprogesterone derivative) when the cells were cultured in 1% of FCS, EGF and 
insulin. It is indeed plausible that in this 'poor medium,' cell apoptosis would be triggered by exposure to 
progestin, while in the standard 5% serum medium culture conditions used here the cells are protected against 
apoptosis triggered by deprivation conditions. Such protection would not be sufficient to prevent the induction of 
apoptosis by a stronger stimulus, such as progestin withdrawal from the culture medium in our conditions. 
Altogether this in vitro and in vivo study suggests that progestin deprivation contributes to the regulation of 
apoptosis in normal but not in abnormal breast epithelium. 
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